JP2024515828A - デユビキチナーゼ標的化キメラ及び関連する方法 - Google Patents

デユビキチナーゼ標的化キメラ及び関連する方法 Download PDF

Info

Publication number
JP2024515828A
JP2024515828A JP2023566513A JP2023566513A JP2024515828A JP 2024515828 A JP2024515828 A JP 2024515828A JP 2023566513 A JP2023566513 A JP 2023566513A JP 2023566513 A JP2023566513 A JP 2023566513A JP 2024515828 A JP2024515828 A JP 2024515828A
Authority
JP
Japan
Prior art keywords
pharma
tautomer
stereoisomer
solvate
hydrate
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2023566513A
Other languages
English (en)
Japanese (ja)
Other versions
JP2024515828A5 (enExample
Inventor
リディア ボイク，
ダスティン リアード ドヴァラ，
ナサニエル ジェイムズ ヘニング，
マシュー ジェイムズ ヘッセ，
ガン リウ，
ジェフリー エム． マッケナ，
ダニエル ケー． ノムラ，
マルクス エーバーハルト シルレ，
ジェシカ ニコル スプラドリン，
ジョン エー． タラリコ，
カール シー． ウォード，
メリッサ ピゲッティ，
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of California, San Diego
Original Assignee
University of California, San Diego
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of California, San Diego filed Critical University of California, San Diego
Publication of JP2024515828A publication Critical patent/JP2024515828A/ja
Publication of JP2024515828A5 publication Critical patent/JP2024515828A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/55—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound the modifying agent being also a pharmacologically or therapeutically active agent, i.e. the entire conjugate being a codrug
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D241/00—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
    • C07D241/02—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings
    • C07D241/06—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having one or two double bonds between ring members or between ring members and non-ring members
    • C07D241/08—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having one or two double bonds between ring members or between ring members and non-ring members with oxygen atoms directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pulmonology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicinal Preparation (AREA)
JP2023566513A 2021-04-29 2022-04-29 デユビキチナーゼ標的化キメラ及び関連する方法 Pending JP2024515828A (ja)

Applications Claiming Priority (9)

Application Number Priority Date Filing Date Title
US202163181796P 2021-04-29 2021-04-29
US63/181,796 2021-04-29
US202163186739P 2021-05-10 2021-05-10
US63/186,739 2021-05-10
US202163273118P 2021-10-28 2021-10-28
US63/273,118 2021-10-28
US202263311781P 2022-02-18 2022-02-18
US63/311,781 2022-02-18
PCT/US2022/027120 WO2022232634A1 (en) 2021-04-29 2022-04-29 Deubiquitinase-targeting chimeras and related methods

Publications (2)

Publication Number Publication Date
JP2024515828A true JP2024515828A (ja) 2024-04-10
JP2024515828A5 JP2024515828A5 (enExample) 2025-05-12

Family

ID=81748638

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2023566513A Pending JP2024515828A (ja) 2021-04-29 2022-04-29 デユビキチナーゼ標的化キメラ及び関連する方法

Country Status (11)

Country Link
US (1) US20240252655A1 (enExample)
EP (1) EP4329815A1 (enExample)
JP (1) JP2024515828A (enExample)
KR (1) KR20240004584A (enExample)
CN (1) CN120225225A (enExample)
AU (1) AU2022265718A1 (enExample)
BR (1) BR112023022315A2 (enExample)
CA (1) CA3216614A1 (enExample)
IL (1) IL307863A (enExample)
MX (1) MX2023012852A (enExample)
WO (1) WO2022232634A1 (enExample)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2024220874A2 (en) * 2023-04-21 2024-10-24 Icahn School Of Medicine At Mount Sinai Otub1 small-molecule binders and otub1-recruiting deubiquitinase-targeting chimeras (dubtacs)
WO2024233280A1 (en) * 2023-05-05 2024-11-14 Icahn School Of Medicine At Mount Sinai Heterobifunctional small molecules that deubiquitinylate and stabilize target proteins by recruiting usp7
WO2024264072A2 (en) * 2023-06-23 2024-12-26 Stablix, Inc. Parp inhibitors
CN119350422B (zh) * 2024-12-25 2025-04-04 中国药科大学 一种去泛素化酶靶向嵌合体化合物及其制备方法和应用

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2011505338A (ja) * 2007-11-16 2011-02-24 バーテックス ファーマシューティカルズ インコーポレイテッド Ａｔｐ結合カセットトランスポーターのイソキノリン調節因子
WO2019238816A1 (en) * 2018-06-13 2019-12-19 University Of Dundee Bifunctional molecules for targeting uchl5
WO2020069105A1 (en) * 2018-09-27 2020-04-02 Dana-Farber Cancer Institute, Inc. Degraders of wee1 kinase
WO2020169650A1 (en) * 2019-02-21 2020-08-27 Locki Therapeutics Limited Survival-targeting chimeric (surtac) molecules
WO2021146390A1 (en) * 2020-01-14 2021-07-22 The Trustees Of Columbia University In The City Of New York Compositions and methods for targeted protein stabilization by redirecting endogenous deubiquitinases

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2008109031A (ru) 2005-08-11 2009-09-20 Вертекс Фармасьютикалз Инкорпорейтед (Us) Модуляторы муковисцидозного трансмембранного регулятора проводимости
LT1993360T (lt) 2005-12-28 2017-06-12 Vertex Pharmaceuticals Incorporated N-[2,4-bis(1,1-dimetiletil)-5-hidroksifenil]-1,4-dihidro-4-oksochinolin-3-karboksamido kieta forma
PE20080695A1 (es) 2006-04-27 2008-06-28 Banyu Pharma Co Ltd Derivados de dihidropirazolopirimidinona como inhibidores de quinasa weel
PL2168966T3 (pl) 2007-06-15 2017-06-30 Msd K.K. Pochodna bicykloaniliny
US20110035601A1 (en) 2007-12-21 2011-02-10 University Of Virginia Patent Foundation System, method and computer program product for protecting software via continuous anti-tampering and obfuscation transforms
EP2303885B1 (en) 2008-06-12 2013-07-03 Merck Sharp & Dohme Corp. Process for producing bicycloaniline derivatives
CZ2009620A3 (cs) 2009-09-22 2011-04-06 Ústav makromolekulární chemie AV CR, v.v.i. Surovina pro výrobu polyurethanu a zpusob její výroby z odpadního polyurethanu
US8247436B2 (en) 2010-03-19 2012-08-21 Novartis Ag Pyridine and pyrazine derivative for the treatment of CF
WO2011133953A1 (en) 2010-04-22 2011-10-27 Vertex Pharmaceuticals Incorporated Pharmaceutical compositions and administrations thereof
KR20150097660A (ko) 2012-12-19 2015-08-26 노파르티스 아게 Cftr 채널을 억제하기 위한 트리시클릭 화합물
CA2895656A1 (en) 2012-12-19 2014-06-26 Novartis Ag Tricyclic compounds as cftr inhibitors
WO2018037350A1 (en) 2016-08-23 2018-03-01 Laurus Labs Limited Solid forms of lumacaftor, process for its preparation and pharmaceutical compositions thereof

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2011505338A (ja) * 2007-11-16 2011-02-24 バーテックス ファーマシューティカルズ インコーポレイテッド Ａｔｐ結合カセットトランスポーターのイソキノリン調節因子
WO2019238816A1 (en) * 2018-06-13 2019-12-19 University Of Dundee Bifunctional molecules for targeting uchl5
WO2020069105A1 (en) * 2018-09-27 2020-04-02 Dana-Farber Cancer Institute, Inc. Degraders of wee1 kinase
WO2020169650A1 (en) * 2019-02-21 2020-08-27 Locki Therapeutics Limited Survival-targeting chimeric (surtac) molecules
WO2021146390A1 (en) * 2020-01-14 2021-07-22 The Trustees Of Columbia University In The City Of New York Compositions and methods for targeted protein stabilization by redirecting endogenous deubiquitinases

Also Published As

Publication number Publication date
EP4329815A1 (en) 2024-03-06
CA3216614A1 (en) 2022-11-03
CN120225225A (zh) 2025-06-27
MX2023012852A (es) 2024-01-15
US20240252655A1 (en) 2024-08-01
WO2022232634A1 (en) 2022-11-03
BR112023022315A2 (pt) 2024-02-20
IL307863A (en) 2023-12-01
AU2022265718A1 (en) 2023-11-02
KR20240004584A (ko) 2024-01-11

Similar Documents

Publication Publication Date Title
US20250122194A1 (en) Novel small molecule inhibitors of tead transcription factors
JP7005582B2 (ja) ブルトン型チロシンキナーゼ（ｂｔｋ）インヒビターとしての多フルオロ置換化合物
JP7785663B2 (ja) 二機能性分解誘導薬及びそれらの使用方法
JP7584815B2 (ja) 抗腫瘍薬物における芳香族化合物及びその用途
US20240252655A1 (en) Deubiquitinase-targeting chimeras and related methods
EP2935249B1 (en) Autotaxin inhibitors
CA2957046C (en) Optionally fused heterocyclyl-substituted derivatives of pyrimidine useful for the treatment of inflammatory, metabolic, oncologic and autoimmune diseases
JP6885999B2 (ja) 水溶性プロドラッグ
WO2024067744A1 (zh) 杂环取代喹唑啉及其制备方法和应用
CN114057771B (zh) 大环化合物及其制备方法和应用
IL262722A (en) Compounds from combined pressure response modulators, preparations containing them and their uses
TW201331177A (zh) 治療活性組合物及其使用方法
EA015103B1 (ru) Производные n-фенил-2-пиримидинамина и способ их получения
JP2017502960A (ja) ベンズアミド及びニコチンアミド化合物及びこれを使用する方法
CN112243437A (zh) 含丙烯酰基的核转运调节剂及其用途
WO2023129564A9 (en) Degraders of grk2 and uses thereof
WO2022229615A1 (en) Compounds
WO2021201036A1 (ja) ヒドロキシピロリジン誘導体およびその医薬用途
US10590101B2 (en) Benzo-N-hydroxy amide compounds having antitumor activity
EP4556465A1 (en) Novel bicyclic pd-l1 inhibitors, preparation methods therefor and medicinal uses thereof
JP6736659B2 (ja) 疼痛のための治療化合物及びその合成
WO2024097355A1 (en) Deubiquitinase-targeting chimeras and related methods
EP4631931A1 (en) Hdac inhibitor and use thereof
Calder et al. The Design, Synthesis, and Evaluation of Hypoxia-Activated Prodrugs of the KDAC Inhibitor Panobinostat
CN122055172A (zh) 靶向质子感应受体gpr4的嵌合放射性药物

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20250430

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20250430

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20260603